secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2021-11-19T23:59:59+00:00
Accession:  0001493152-21-029397
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics appoints Samuel J. Reich as Executive Chairman; $350K salary, 350K share option.
--------------------------------------------------------------------------------

- Reich named Executive Chairman effective Oct 25, 2021; reports to Board of Directors.
- Annual base salary of $350,000; eligible for annual cash bonus of at least 50% of base salary.
- Granted nonqualified stock option for 350,000 shares vesting over three years (1/3 year 1, remainder monthly).
- Severance: 12 months salary + COBRA if terminated without cause/good reason; 24 months if in change of control period.
- Agreement includes standard restrictive covenants (non-disclosure, non-compete, non-solicitation).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000149315221029397/0001493152-21-029397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000149315221029397/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-029397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer